Current Affairs PDF

CSIR approves project to develop ‘hmAbs’ that can neutralize SARS-CoV-2 in patients; BBIL to lead

AffairsCloud YouTube Channel - Click Here

AffairsCloud APP Click Here

CSIR approves project to develop 'hmAbs'Council of Scientific and Industrial Research (CSIR) through its New Millennium Indian Technology Leadership Initiative (NMITLI) program has approved a project for the development of human monoclonal antibodies (hmAbs) that can neutralize SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in patients.

Implemented by collaboration of institutes; BBIL to lead

It will be implemented through a collaboration ofNational Centre for Cell Science (NCCS) Pune; Indian Institute of Technology(IIT),Indore;PredOmixTechnologies Ltd,Gurugram;and Bharat Biotech International Ltd (BBIL),Hyderabad.

  • The project will be led by Vaccines and biotherapeutics maker BBIL.
  • It will also be the commercial partner and responsible for subsequent development and commercialization of the hmAbs generated.
  • It should be noted that recently,Indian Council of Medical Research (ICMR) has also partnered with BBIL to develop a fully indigenous vaccine for Covid-19.

About hmAbs:

Monoclonal antibody therapy is a form of immunotherapy designed to produce immunity to a disease or to enhance resistance by the immune system. This new project aims to generate hmAbsto SARS-CoV-2 from the gradual recovery phase of COVID-19 patients and select high affinity and neutralizing antibodies.

  • The project also generateshmAbs clones that can neutralize the mutated virus so that it could be readily used for combating future SARS-CoV infections.

NMITLI is a flagship program of CSIR aimed to support new ideas and projects from academic institutions and industries.

About CSIR:
Works under– Ministry of Science & Technology
Director General– Dr. Shekhar C. Mande

About BBIL:
Found & Chairman and Managing Director (CMD)– Dr. Krishna M. Ella
Headquarter– Hyderabad, Telangana